16 Photo

Synthetic Biologics, Inc. (NYSE MKT: SYN) is a late-stage clinical company developing therapeutics focused on the microbiome. The Company's lead gut microbiome-focused programs poised for Phase 3 development include SYN-004 (ribaxamase), designed to protect the gut microbiome from the deleterious effects of commonly used intravenous (IV) beta-lactam antibiotics for the prevention of primary C. difficile infection, antibiotic-associated diarrhea (AAD) and the emergence of antimicrobial resistance (AMR), and SYN-010 a proprietary, modified-release formulation of lovastatin lactone intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C).

Copyright © 2017-2018 Allied Academies, All Rights Reserved.